Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||17 Dec 2018||Lorem|
|Xencor reassesses XmAB5871 design for Phase III IgG4-RD study after SLE failure; YE18 target start, CMO says||26 Oct 2018||Krystnell Storr|
|Xencor’s XmAb5871 receives tepid response to Phase II lupus study; trial design a catch-22 for short and long-term efficacy, experts say||30 Aug 2018||Krystnell Storr|
|Xencor’s asthma drug XmAb7195 completes Phase Ia enrollment - CEO||08 Dec 2015||Alissa Fleck|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer